ArticleFrontiers in medicine2026
Clinical utility of combined serum IL-6, PCT, and SAA assays for early diagnosis and severity stratification of neonatal sepsis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Neonatal sepsis continues to be a leading cause of death and disability in newborns worldwide. Early identification is difficult due to vague and overlapping clinical signs. Reliance on a single biomarker often yields suboptimal sensitivity or specificity. This study aimed to assess the added clinical value of combining serum interleukin-6 (IL-6), procalcitonin (PCT), and serum amyloid A (SAA) for the early recognition and severity grading of neonatal sepsis. Methods: A total of 140 neonates admitted to the neonatal intensive care unit (NICU) between January 2022 and December 2023 were enrolled. Based on clinical criteria and blood culture results, they were assigned to three groups: confirmed sepsis ( Results: Serum levels of IL-6, PCT, and SAA were markedly higher in the confirmed sepsis group than in the suspected sepsis and control groups (all Conclusion: Simultaneous measurement of serum IL-6, PCT, and SAA substantially enhances early diagnostic accuracy for neonatal sepsis and helps differentiate disease severity. This panel can serve as a rapid, reliable, and minimally invasive adjunct to blood culture in the NICU setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.